Agilent Names John Palma to Lead Global Medical Affairs Organization
November 02 2021 - 2:00PM
Business Wire
Agilent Technologies, Inc. (NYSE: A) today announced that John
Palma has joined the company as vice president, Medical Affairs. In
this role, he will build and lead the companywide Global Medical
Affairs organization.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211102006093/en/
John Palma, Agilent vice president of
Medical Affairs. (Photo: Business Wire)
Palma has more than 26 years of experience in the development,
management, and delivery of complex diagnostics and research
products. He has consulted with global, clinical, and key opinion
leaders for the advancement of high medical value companion
diagnostics and has been engaged in working across the pathology
and molecular laboratory customer segments. Palma’s background
includes deep expertise in the design and execution of liquid
biopsy strategy, including clinical studies, health outcomes,
development, and management.
“We’re extremely pleased John has joined the Agilent team,” said
Dr. Kate Knobil, Agilent chief medical officer. “His role will be
critical to establishing our Global Medical Affairs organization as
he drives important links across our commercial, marketing, R&D
and quality and regulatory affairs organizations. John’s experience
will create new capabilities for us as we expand our presence in
next generation sequencing, and he will be key to our efforts
driving Agilent strategy for liquid biopsy development.”
Prior to joining Agilent, Palma served in several roles at Roche
over the last 10 years. Most recently, he was vice president, head
of Medical & Scientific Affairs and chief medical officer for
the Roche Sequencing Solutions business.
“John’s insights and background will help us expand our position
in cancer diagnostics, and specifically in precision oncology,”
said Sam Raha, president of Agilent’s Diagnostics and Genomics
Group. “His addition builds on our acquisition of Resolution
Bioscience earlier this year and reaffirms our commitment to being
a preferred partner to pharmaceutical companies for companion
diagnostic development, registration and commercialization, and to
clinical labs around the world for cancer diagnostic testing.”
In addition to memberships across a broad list of medical
professional organizations, Palma has been involved in six
successful patent application awards and has co-authored more than
three dozen technical papers.
Palma received his bachelor’s degree in biology from Manhattan
College and his doctorate in microbiology and immunology from State
University of New York, Downstate.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets, delivering
insight and innovation toward improving the quality of life.
Agilent instruments, software, services, solutions, and people
provide trusted answers to customers' most challenging questions.
The company generated revenue of $5.34 billion in fiscal year 2020
and employs 16,400 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
please subscribe to the Agilent Newsroom. Follow Agilent on
LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211102006093/en/
Tom Beermann +1 408 386 5892 tom.beermann@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024